Effects of dupilumab treatment on patch test reactions: A retrospective evaluation.
Ontology highlight
ABSTRACT:
SUBMITTER: de Wijs LEM
PROVIDER: S-EPMC8362223 | biostudies-literature | 2021 Jul
REPOSITORIES: biostudies-literature
Publications
Effects of dupilumab treatment on patch test reactions: A retrospective evaluation.
de Wijs Linde E M LEM van der Waa José D JD Nijsten Tamar T Silverberg Jonathan I JI Kunkeler Amalia C M ACM Hijnen Dirk J DJ
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20210530 7
Similar Datasets
Project description:BackgroundNot performing a day (D) 7 patch test reading might result in positive patch test reactions being missed.ObjectivesTo investigate the added value of the D7 patch test reading for individual allergens, and to identify patient characteristics and allergen groups associated with new positive D7 reactions.MethodsData from patients patch tested between 2008 and 2018 with the extended European baseline series were analysed. Patch test readings were performed on D3 and D7. Positive reactions were categorized into positive on D3 or new positive on D7.ResultsA total of 3292 patients were consecutively patch tested with at least 43 allergens of the TRUE Test panels 1 and 2 supplemented with investigator-loaded allergens. In total, 447 (13.6%) patients showed new positive D7 reactions. In univariable regression analysis, age between 18 and 30 years showed a negative association with new positive D7 reactions. Significantly more D7 positive reactions were seen for topicals (odds ratio [OR] 2.60, 95% confidence interval [CI]: 1.92-3.51) and corticosteroids (OR 1.87, 95%CI: 1.09-3.21). No associations were found between sex, atopic dermatitis and occupational dermatitis and a new positive D7 reaction.ConclusionA D7 reading to identify new positive patch test reactions is of added value, especially for topicals and corticosteroids.
| S-EPMC6771944 | biostudies-literature
Project description:Background: Immune mechanisms underlying elicitation in allergic contact dermatitis (ACD) are not disclosed. Previous studies have shown a double-faceted nature of ACD with both common biomarkers between different allergens, as well as allergen-specific imprinting, with discordance in terms of relevant involved immune pathways. Objectives: To characterize molecular signatures and their immune mechanisms between different relevant allergens (nickel, 2-hydroxyethylmethacrylate (2-HEMA), methylisothiazolinone (MI), formaldehyde) in strong and extreme patch test reactions of patients without atopic dermatitis using RNA sequencing.
2025-07-16 | GSE282562 | GEO
Project description:BackgroundTitanium is being increasingly used. Although it is considered to be a non-allergenic material, allergic reactions to it have been reported. Titanium dioxide has been found to be an unreliable patch test material. Few studies to date have profiled titanium allergy, and it therefore remains difficult to distinguish its manifestations.ObjectivesTo evaluate alternatives for titanium dioxide as a patch test preparation, and to profile titanium reactions and manifestations.MethodsA retrospective chart review was conducted with 458 patients who underwent patch testing with at least 1 of 5 different titanium salts.ResultsAt least 1 positive result was noted in 5.7% of the patients. The frequency of positive results for the tested salts ranged from 0.9% to 7.9%. Titanium(IV) oxalate hydrate had the highest yield and titanium dioxide the lowest. Erythema, dermatitis and local swelling were the most common objective complaints. In 16 (61.5%) patients, the test result had partial or full clinical relevance.ConclusionsNo titanium-specific risk factors and clinical picture could be identified. Titanium dioxide is not adequately sensitive for identifying titanium allergy. The titanium salts seem to be possible superior patch test preparations, but appear to be unsuitable if used singly. The patient's medical history and clinical picture remain crucial in the diagnostic work-up.
| S-EPMC6099462 | biostudies-literature
Project description:ImportanceContact dermatitis in the anogenital area is associated with sleep disturbance and dyspareunia and can profoundly affect quality of life. The literature on anogenital contact dermatitis and culprit allergens is limited. The last large-scale study on common, relevant allergens in patients with anogenital dermatitis was published in 2008.ObjectivesTo characterize patients with anogenital dermatitis referred for patch testing by the North American Contact Dermatitis Group, to identify common allergens, and to explore sex-associated differences between anogenital dermatitis and allergens.Design, setting, and participantsA retrospective, cross-sectional analysis was conducted of the North American Contact Dermatitis Group database among 28 481 patients who underwent patch testing from January 1, 2005, to December 31, 2016, at outpatient referral clinics in the United States and Canada.ExposurePatch testing for allergens.Main outcomes and measuresCurrently relevant allergic patch test reactions in patients with anogenital dermatitis.ResultsOf 28 481 patients tested during the study period, 832 patients (336 men and 496 women; mean [SD] age, 50.1 [26.5] years) had anogenital involvement and 449 patients (177 men and 272 women; mean [SD] age, 49.6 [17.4] years) had anogenital dermatitis only. Compared with those without anogenital involvement, there were significantly more male patients in the group with anogenital dermatitis (177 [39.4%] vs 8857 of 27 649 [32.0%]; relative risk, 1.37; 95% CI, 1.14-1.66; P < .001). In the group with anogenital involvement, female patients were significantly less likely than male patients to have allergic contact dermatitis as a final diagnosis (130 [47.8%] vs 107 [60.5%]; relative risk, 0.78; 95% CI, 0.64-0.94; P = .01), whereas a final diagnosis of other dermatoses (eg, lichen planus, lichen sclerosus, or lichen simplex chronicus) was more frequent for female patients than for male patients (67 [24.6%] vs 28 [15.8%]; relative risk, 1.54; 95% CI, 1.02-2.31; P = .03). Of the 449 patients in the group with anogenital involvement only, 227 (50.6%) had 1 or more relevant reaction with patch testing. Allergens that were statistically significantly more common in patients with anogenital involvement compared with those without anogenital involvement included medicaments such as dibucaine (10 of 250 patients tested [4.0%] vs 32 of 17 494 patients tested [0.2%]; relative risk, 22.74; 95% CI, 11.05-46.78; P < .001) and preservatives such as methylchloroisothiazolinone and methylisothiazolinone (30 of 449 patients tested [6.7%] vs 1143 of 27 599 patients tested [4.1%]; relative risk, 1.61; 95% CI, 1.14-2.41; P = .008). A total of 152 patients met the definition for anogenital allergic contact dermatitis, which is defined as anogenital involvement only, allergic contact dermatitis as the only diagnosis, and 1 or more positive reaction of current clinical relevance.Conclusions and relevanceFor patients with anogenital involvement only who were referred for patch testing, male patients were more likely to have allergic contact dermatitis, whereas female patients were more likely to have other dermatoses. Common allergens or sources consisted of those likely to contact the anogenital area. For individuals with anogenital involvement suspected of having allergic contact dermatitis, reactions to preservatives, fragrances, medications (particularly topical anesthetics), and topical corticosteroids should be tested.
| S-EPMC6902099 | biostudies-literature
Project description:Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or IgE-levels benefit greater from dupilumab therapy. Moreover, there is no data comparing the efficacy of functional endoscopic sinus surgery (FESS) with dupilumab therapy. We conducted a retrospective chart review of all patients that were treated at a tertiary referral center for CRswNP with dupilumab. We also contacted the patients with a questionnaire to evaluate the efficacy of previous surgeries and dupilumab therapy by visual analogue scale (VAS) and the glasgow benefit inventory (GBI) as well as report on side effects. Overall, 75 patients were included in the study at hand that reported back 138 times. While dupilumab treatment was efficient, we found no systematic evidence of greater efficacy of dupilumab in patients with AERD, histologic eosinophilia or increased blood eosinophil or IgE-levels. All patients showed a considerable decrease in subjective burden of disease, objective smell tests and endoscopic findings. From the patients point of view, dupilumab therapy showed greater efficacy both in the VAS and the GBI overall and all subcategories but "social support." Dupilumab is efficient in treating CRSwNP; this effect is independent from disease characteristics like AERD, histologic eosinophilia, serum IgE-levels or eosinophil counts. There seems to be a group of patients that benefit greater from dupilumab therapy compared to FESS.
| S-EPMC9666224 | biostudies-literature
Project description:ImportanceSince the increased use of dupilumab for atopic dermatitis (AD) in daily practice, several cases have been reported on the development of cutaneous T-cell lymphomas (CTCL) and lymphoid infiltrates.ObjectiveTo provide insight in the clinical and histopathologic features of patients with AD clinically suspected for CTCL during dupilumab treatment.Design, setting, and participantsThis retrospective observational case series included adult (≥18 years) patients with AD treated with dupilumab between October 2017 and July 2022 at the University Medical Center Utrecht in the Netherlands.Main outcomes and measuresRelevant patient, disease, and treatment characteristics were evaluated. Skin biopsies before, during, and after treatment were collected and reassessed.ResultsFourteen patients (54.5% male) with a median (IQR) age of 56 (36-66) years suspected for CTCL with deterioration of symptoms during dupilumab treatment were included. Of 14 patients, 3 were retrospectively diagnosed with preexistent mycosis fungoides (MF). Eleven patients with AD were eventually diagnosed with a lymphoid reaction (LR). These patients showed MF-like symptoms; however, histopathologic findings were different, and included sprinkled distribution of small hyperchromatic lymphocytes in the upper epidermal section, a dysregulated CD4:CD8 ratio, and CD30 overexpression, without loss of CD2/CD3/CD5. The median time to clinical worsening was 4.0 months (IQR, 1.4-10.0). Posttreatment biopsies showed complete clearance of the LR in all patients.Conclusions and relevanceThis study found that dupilumab treatment can cause a reversible and benign LR, which mimics a CTCL, though has distinctive histopathologic features.
| S-EPMC10585590 | biostudies-literature
Project description:Donor-matched human skin biopsies were taken from non-lesional (NL) and lesional skin of positive patch-test reactions to nickel at 24h, 48h, and 120h post allergen application, respectively, and bulk RNA-seq was performed.
2022-10-31 | E-MTAB-12237 | biostudies-arrayexpress
Project description: Not available
| S-EPMC10120610 | biostudies-literature
Project description:To investigate the effect in the patients with Netherton syndrome, four different patients was evaluated at two time points using single-cell RNA sequencing.
2022-12-28 | GSE214985 | GEO
Project description:Patch evaluation prednisolone. Run on the Q-Exactive in positive ionisation mode.
2017-06-20 | MSV000081176 | GNPS